Gate Bioscience and Lilly Expand Deal
Gate Bioscience expanded its research agreement with Eli Lilly to develop treatments targeting disease-causing proteins. The deal is potentially worth over $870 million and adds a new drug target to the collaboration.
Xurve View
Insights:
Xurve View
Gate Bioscience expanded its research partnership with ELI LILLY & CO in a deal valued at more than $870M. The partnership targets disease-causing proteins through oral small-molecule drugs. The agreement builds on an initial July 2025 pact worth up to $856M.
